Teleflex (NYSE:TFX – Get Free Report) and Solana (NASDAQ:HSDT – Get Free Report) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, profitability, risk, analyst recommendations, institutional ownership, dividends and earnings.
Institutional and Insider Ownership
95.6% of Teleflex shares are owned by institutional investors. Comparatively, 18.6% of Solana shares are owned by institutional investors. 0.7% of Teleflex shares are owned by insiders. Comparatively, 14.4% of Solana shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Earnings & Valuation
This table compares Teleflex and Solana”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Teleflex | $1.99 billion | 2.89 | -$905.64 million | ($22.80) | -5.71 |
| Solana | $6.02 million | 21.73 | -$40.89 million | ($109.67) | -0.02 |
Solana has lower revenue, but higher earnings than Teleflex. Teleflex is trading at a lower price-to-earnings ratio than Solana, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Teleflex has a beta of 0.82, indicating that its stock price is 18% less volatile than the S&P 500. Comparatively, Solana has a beta of 1.06, indicating that its stock price is 6% more volatile than the S&P 500.
Profitability
This table compares Teleflex and Solana’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Teleflex | -35.88% | 13.29% | 6.55% |
| Solana | -1,427.15% | -67.57% | -24.09% |
Analyst Recommendations
This is a breakdown of recent ratings and recommmendations for Teleflex and Solana, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Teleflex | 1 | 5 | 3 | 0 | 2.22 |
| Solana | 1 | 1 | 1 | 1 | 2.50 |
Teleflex presently has a consensus target price of $144.00, indicating a potential upside of 10.59%. Solana has a consensus target price of $3.50, indicating a potential upside of 56.25%. Given Solana’s stronger consensus rating and higher probable upside, analysts plainly believe Solana is more favorable than Teleflex.
Summary
Solana beats Teleflex on 8 of the 15 factors compared between the two stocks.
About Teleflex
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site. It also offers interventional products, which consists of various coronary catheters, structural heart support devices, and peripheral intervention and mechanical circulatory support platform that are used by interventional cardiologists and radiologists, and vascular surgeons; and Arrow branded pumps and catheters, Guideline, Turnpike, and Trapliner catheters, the Manta Vascular Closure, and Arrow Oncontrol devices. The company provides anesthesia products, such as airway and pain management products to support hospital, emergency medicine, and military channels; and surgical products, including metal and polymer ligation clips, and fascial closure surgical systems that are used in laparoscopic surgical procedures, percutaneous surgical systems, and other surgical instruments. It also offers interventional urology products comprising the UroLift System, an invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia; respiratory products, including oxygen and aerosol therapies, spirometry, and ventilation management products for use in various care settings; urology products, such as catheters, urine collectors, and catheterization accessories and products for operative endourology; and bladder management services. The company serves hospitals and healthcare providers, medical device manufacturers, and home care markets. Teleflex Incorporated was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.
About Solana
Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-implantable technologies for the treatment of symptoms caused by neurological disease or trauma. The company's product is Portable Neuromodulation Stimulator, a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise. The company was incorporated in 2014 and is headquartered in Newtown, Pennsylvania.
Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with MarketBeat.com's FREE daily email newsletter.
